At the 5th Wet AMD & Diabetic Eye Disease Summit, you have access to a premier platform to showcase your pioneering solutions and expertise in retinal diseases. Engage with senior decision-makers from leading biopharma companies, including Bayer, Aviceda Therapeutics, Ocular Therapeutix, Sanofi, Opus Genetics, Ocugen, and Outlook Therapeutics. This summit presents an unparalleled opportunity for service providers to connect with industry leaders advancing the next generation of therapies for wet AMD and diabetic eye disease.
By offering specialized solutions in key areas such as advanced image analysis through image reading centres, comprehensive support from clinical and preclinical CROs, cutting-edge AI platforms for data analysis, and innovative drug delivery services, your organization will position itself as the go-to partner for biopharma developers and researchers. Biopharma are in need of these crucial services in a competitive market to optimize clinical trial designs, accelerate drug development, ensure precise patient stratification, and enhance the delivery and efficacy of treatments for retinal diseases like wet AMD and diabetic eye disease.
With opportunities to present, network one-on-one with industry leaders, and enhance your brand visibility, explore a tailored partnership package that aligns with your strategic objectives, ensuring your innovations take center stage in the fight vision loss.
Past Partners
Wet AMD & Diabetic Drug Developers are Actively Seeking New Collaborations to:
Ensuring Accurate Diagnostics: Accurately assessing treatment efficacy in retinal diseases is a challenge due to the complexity of retinal images and variability in patient responses. By providing expert analysis of ophthalmic images, image reading centres validate biomarkers and refine clinical endpoints, enhancing trial accuracy
Streamlining Patient Recruitment & Stratification: Recruiting and stratifying patients effectively is difficult due to the diverse nature of retinal diseases and the need to match patients with the right treatments. Clinical CROs optimize trial designs and improve patient monitoring, ensuring better recruitment strategies and increasing trial success rates for wet AMD and diabetic eye disease
Ensuring Safety & Efficacy in Early Stages: Identifying safe and effective drug candidates early is challenging because of the lack of predictive models and the difficulty in translating preclinical results to human trials. Preclinical CROs and model providers address this by rigorously testing candidates' safety and efficacy, ensuring that only the most promising treatments move forward
Accelerating Development with AI: Analyzing large datasets and predicting treatment responses is complex due to the sheer volume of data and the need for precise insights. By processing vast amounts of trial data, AI platforms optimize recruitment, identify new drug targets, and accelerate the development of retinal disease treatments
Improving Drug Delivery Precision: Delivering therapies effectively to the eye is a challenge due to the unique anatomy of the eye and the difficulty in ensuring drugs reach the targeted area. Drug delivery services ensure precise formulation and targeted delivery, improving patient adherence and enhancing the effectiveness of treatments for retinal diseases
Why Partner?
Forge Valuable Connections with Key Decision Makers: Engage with senior leaders from biopharma and research institutions as they explore new collaborations and push towards FDA approvals in the development of treatments for wet AMD and diabetic eye disease
Enhance Your Brand Visibility: Explore innovative presenting, marketing, and branding opportunities that will position your company as a preferred partner in the retinal disease space, highlighting your expertise in advancing retinal vascular disease therapeutics
Showcase Your Solutions & Expertise: Leverage our audience of biopharma stakeholders actively seeking high-quality support and collaboration opportunities to showcase your unique services for retinal vascular disorder treatments
Who Will You Meet?
